Diese Seite wurde automatisch übersetzt und die Genauigkeit der Übersetzung wird nicht garantiert. Bitte wende dich an die englische Version für einen Quelltext.

A Study of Tocilizumab Added to DMARDs in Patients With Moderate to Severe Rheumatoid Arthritis and an Inadequate Response to DMARDs.

28. Februar 2018 aktualisiert von: Hoffmann-La Roche

Local Open-label Multicenter Study to Evaluate the Quality of Life in Patients With Moderate to Severe Active Rheumatoid Arthritis and an Inadequate Response to DMARDs When Adding Tocilizumab (TCZ)

This open-label single arm study will evaluate the efficacy and safety of tocilizumab added to traditional disease-modifying antirheumatic drugs (DMARDs) in patients with moderate to severe active rheumatoid arthritis and an inadequate response to DMARDs. Patients will receive tocilizumab 8 mg/kg by intravenous infusion every 4 weeks for 24 weeks, in addition to their current non-biologic DMARDs at stable doses. Anticipated time on study treatment is 24 weeks, and the target sample size is 200.

Studienübersicht

Studientyp

Interventionell

Einschreibung (Tatsächlich)

201

Phase

  • Phase 4

Kontakte und Standorte

Dieser Abschnitt enthält die Kontaktdaten derjenigen, die die Studie durchführen, und Informationen darüber, wo diese Studie durchgeführt wird.

Studienorte

      • Chelyabinsk, Russische Föderation, 454076
        • Chelyabinsk Regional Clinical Hospital; Rheumatology
      • Cherkess, Russische Föderation, 369000
        • Republican clinical hospital of Karachai-Cherkess; Rheumatologic Department
      • Ekaterinburg, Russische Föderation, 620102
        • Municipal Autonomous Institution of Healthcare "City Clinical Hospital #40"
      • Ekaterinburg, Russische Föderation, 620102
        • Sverdlovsk Regional Clinical Hospital # 1; Rheumatology Dept
      • Irkutsk, Russische Föderation, 664047
        • Irkutsk Regional Consulting and Diagnostic Clinical Center; Regional Center of Reumatolodic Deasise
      • Izhevsk, Russische Föderation, 426009
        • Republican Clinicodiagnostic Center
      • Kaliningrad, Russische Föderation, 236016
        • Kaliningrad Regional Clinical Hospital; Rheumatologic Department
      • Kemerovo, Russische Föderation, 650099
        • War Veterans Regional Clinical Hospital;Therapy Department
      • Kirov, Russische Föderation, 610028
        • Kirov Regional Clinical Hospital; Reumatology Department
      • Krasnodar, Russische Föderation, 350086
        • GUZ Regional clinical hospital # 1
      • Kursk, Russische Föderation, 305007
        • GMU Kursk regional clinical hospital
      • Moscow, Russische Föderation, 123060
        • Head Clinical Hospital of Internal Affair Ministry of Russia
      • Moscow, Russische Föderation, 129110
        • Vladimirskiy Regional Scientific Research Inst.
      • Moscow, Russische Föderation, 115522
        • FSBI "Scientific Research Institute of Rheumatology" of russian Academy of Medical Sciences
      • Moscow, Russische Föderation, 115682
        • FSBI "FSCC of particularized sorts of medical care and medical technologies of FMBA"
      • Moscow, Russische Föderation, 121359
        • FGU Central Clinical Hospital with Polyclinic Administration President RF
      • Nizhny Novgorod, Russische Föderation, 603126
        • SIH Nizhny Novgorod Regional Clinical Hospital n.a. Semashko
      • Petrozavodsk, Russische Föderation, 185019
        • Republican Hospital named after V.A. Baranov
      • Rostov-na-Donu, Russische Föderation, 344022
        • Rostov State Medical University; Cardiorheumatology Department
      • Smolensk, Russische Föderation, 214001
        • Clinical hospital #1
      • Surgut, Russische Föderation, 628408
        • Surgut Region Clinical Hospital
      • Tjumen, Russische Föderation, 625023
        • Glpu Tjumen Regional Clinical Hospital #1
      • UFA, Russische Föderation, 450005
        • Republican clinical hospital named after G.G. Kuvatov
      • Ulyanovsk, Russische Föderation, 432063
        • State Institution of Healthcare Ulyanovsk Regional Clinical Hospital
      • Veliky Novgorod, Russische Föderation, 173008
        • GUZ "Novgorod Regional Clinical Hospital"; Cardioreumatological
      • Voronezh, Russische Föderation, 394066
        • Voronezh Regional Clinical Hospital #1
      • Voronezh, Russische Föderation, 394066
        • Budget Institution of Healthcare of Voronezh Region "Voronezh Regional Clinical Hospital #1"
      • Yaroslavl, Russische Föderation, 150062
        • SHI Yaroslavl Regional Clinical Hospital

Teilnahmekriterien

Forscher suchen nach Personen, die einer bestimmten Beschreibung entsprechen, die als Auswahlkriterien bezeichnet werden. Einige Beispiele für diese Kriterien sind der allgemeine Gesundheitszustand einer Person oder frühere Behandlungen.

Zulassungskriterien

Studienberechtigtes Alter

18 Jahre und älter (Erwachsene, Älterer Erwachsener)

Akzeptiert gesunde Freiwillige

Nein

Studienberechtigte Geschlechter

Alle

Beschreibung

Inclusion Criteria:

  • adult patients, >/= 18 years of age
  • moderate to severe active rheumatoid arthritis of >/=6 months duration
  • inadequate clinical response to current non-biologic DMARDs
  • current DMARDs must be at stable dose for 8 weeks prior to study entry
  • oral corticosteroids (</=10mg/day prednisone or equivalent) and NSAIDs must be at stable dose for >/=4 weeks prior to screening

Exclusion Criteria:

  • rheumatic autoimmune disease other than RA
  • history of or current inflammatory joint disease other than RA
  • previous treatment with any biologic DMARD
  • functional class IV as defined by the ACR classification
  • intra-articular or parenteral corticosteroids within 6 weeks prior to screening

Studienplan

Dieser Abschnitt enthält Einzelheiten zum Studienplan, einschließlich des Studiendesigns und der Messung der Studieninhalte.

Wie ist die Studie aufgebaut?

Designdetails

  • Hauptzweck: Behandlung
  • Zuteilung: Nicht randomisiert
  • Interventionsmodell: Einzelgruppenzuweisung
  • Maskierung: Keine (Offenes Etikett)

Waffen und Interventionen

Teilnehmergruppe / Arm
Intervention / Behandlung
Experimental: 1
8 mg/kg iv every 4 weeks for 24 weeks
stable doses at investigator's prescription

Was misst die Studie?

Primäre Ergebnismessungen

Ergebnis Maßnahme
Maßnahmenbeschreibung
Zeitfenster
Health Assessment Questionnaire (HAQ) Score
Zeitfenster: Weeks 0, 4, 8, 12, 16, 20, and 24 and Withdrawal Visit
HAQ includes 20 questions concerning participant's activities of daily life, grouped in 8 scales of 2 to 3 questions for each activity. To respond to each question, a four-level response (score of 0 to 3 points), with higher scores showing larger functional limitations, was chosen. Scoring was as follows with respect to performance of participant's everyday activities: 0 (equals)=without difficulties; 1=with some difficulties; 2=with great difficulties; and 3=unable to perform these actions at all. Minimum score was 0, maximum score was 3. Withdrawal Visit is the final visit prior to the withdrawal of the subject from the study.
Weeks 0, 4, 8, 12, 16, 20, and 24 and Withdrawal Visit
Percentage of Participants With an HAQ Score Decrease of 20 Percent (%), 50%, and 70% During Tocilizumab Treatment
Zeitfenster: Weeks 4, 8, 12, 16, 20, and 24
HAQ includes 20 questions concerning participant's activities of daily life, grouped in 8 scales of 2 to 3 questions for each activity. To respond to each question, a four-level response (score of 0 to 3 points), with higher scores showing larger functional limitations, was chosen. Scoring was as follows with respect to performance of participant's everyday activities: 0=without difficulties; 1=with some difficulties; 2=with great difficulties; and 3=unable to perform these actions at all. Minimum score was 0, maximum score was 3.
Weeks 4, 8, 12, 16, 20, and 24
Change in HAQ Score at Week 24
Zeitfenster: Baseline and Week 24
HAQ includes 20 questions concerning participant's activities of daily life, grouped in 8 scales of 2 to 3 questions for each activity. To respond to each question, a four-level response (score of 0 to 3 points), with higher scores showing larger functional limitations, was chosen. Scoring was as follows with respect to performance of participant's everyday activities: 0=without difficulties; 1=with some difficulties; 2=with great difficulties; and 3=unable to perform these actions at all. Minimum score was 0, maximum score was 3.
Baseline and Week 24

Sekundäre Ergebnismessungen

Ergebnis Maßnahme
Maßnahmenbeschreibung
Zeitfenster
Pain Score as Assessed by Visual Analogue Scale (VAS)
Zeitfenster: Weeks 0, 4, 8, 12, 16, 20, and 24
Participant's global assessment of pain was assessed using a 100-millimeter (mm) horizontal VAS (0 to 100 mm) with 0=pain absent and 100=intolerable pain. Participants responded by placing a mark on the line to indicate their current level of pain.
Weeks 0, 4, 8, 12, 16, 20, and 24
European Quality of Life - 5 Dimensions (EQ-5D) Score
Zeitfenster: Weeks 0, 4, 8, 12, 16, 20, and 24
EQ-5D questionnaire assess 5 domains of quality of life including mobility, self-care, habitual daily activities, pain, discomfort, and anxiety/depression. Each of five domains was assessed by 3 levels depending on severity of a problem and scored using the following: 1=no disturbances, 2=moderate disturbances, 3=severe disturbances. Score is transformed and results in a total score range -0.594 to 1.000; higher score indicates a better health state.
Weeks 0, 4, 8, 12, 16, 20, and 24
Change in EQ-5D Score at Week 24 From Baseline
Zeitfenster: Baseline and Week 24
EQ-5D questionnaire assess 5 domains of quality of life including mobility, self-care, habitual daily activities, pain, discomfort, and anxiety/depression. Each of five domains was assessed by 3 levels depending on severity of a problem and scored using the following: 1=no disturbances, 2=moderate disturbances, 3=severe disturbances. Score is transformed and results in a total score range -0.594 to 1.000; higher score indicates a better health state. Minimum clinically significant change in EQ-5D corresponds to the parameter differences before and after treatment = 0.10. Graduations of assessment of the therapy efficacy by EQ-5D are: Difference (Δ) EQ-5D less than (<)0.10 points: none; 0.10 less than or equal to (≤)Δ EQ-5D ≤0.24: minimal effect; 0.24≤ Δ EQ-5D <0.31: satisfactory effect; Δ EQ-5D greater than or equal to (≥)0.31 points: pronounced effect.
Baseline and Week 24
General Health Score as Assessed by EQ-5D VAS
Zeitfenster: Weeks 0, 4, 8, 12, 16, 20, and 24
Participant-reported general health quality was assessed using an EQ-5D 100-mm horizontal VAS (0 to 100 mm) with 0=worst health state and 100=the best health state. The participants were asked to mark the line that corresponded to assessment of general health quality.
Weeks 0, 4, 8, 12, 16, 20, and 24
Percentage of Participants Achieving a Positive Response on Health Quality Assessment of EQ-5D
Zeitfenster: Weeks 0, 4, 8, 12, 16, 20, and 24
Participant-reported general health quality was assessed using an EQ-5D 100-mm horizontal VAS (0 to 100 mm) with 0=worst health state and 100=the best health state. The participants were asked to mark the line that corresponded to assessment of general health quality. Positive response was defined as an increase of EQ-5D score by 0.1 or more i.e. it is a clinically significant increase.
Weeks 0, 4, 8, 12, 16, 20, and 24
Change in General Health Assessed by VAS
Zeitfenster: Baseline and Week 24
Participant-reported general health quality was assessed using an EQ-5D 100-mm horizontal VAS (0 to 100 mm) with 0=worst health state and 100=the best health state. The participants were asked to mark the line that corresponded to assessment of general health quality.
Baseline and Week 24
Disease Activity Score Based on 28-Joint Count (DAS28)
Zeitfenster: Weeks 0, 4, 8, 12, 16, 20, and 24
DAS28 calculated from the number of swollen joints and tender joints using the 28-joint count, the erythrocyte sedimentation rate (ESR) (millimeters per hour [mm/hour]) and global health assessment (participant rated global assessment of disease activity using 10-mm VAS); DAS28 score ranged from 0 to 10, where higher scores correspond to greater disease activity.
Weeks 0, 4, 8, 12, 16, 20, and 24
Change in DAS28 Score From Baseline to Week 24
Zeitfenster: Baseline and Week 24
Baseline and Week 24
Percentage of Patients With Varied Disease Activity Assessed Using DAS28 During Tocilizumab Treatment
Zeitfenster: Weeks 0, 4, 8, 12, 16, 20, and 24
DAS28 calculated from the number of swollen joints and tender joints using the 28-joint count, the ESR mm/hour, and global health assessment (participant rated global assessment of disease activity using 10-mm VAS); DAS28 score ranged from 0 to 10, where higher scores correspond to greater disease activity. Disease activity: 0=remission (DAS28 less than [<] 2.6), I=low (DAS28 less than or equal to [≤]2.6 to <3.2), II=moderate (DAS28=3.2 to 5.1), III=high (DAS28 greater than [>]5.1).
Weeks 0, 4, 8, 12, 16, 20, and 24
Percentage of Participants Achieving American College of Rheumatology 20% (ACR20), 50% (ACR50), and 70% (ACR70) Response
Zeitfenster: Weeks 0, 4, 8, 12, 16, 20, and 24
ACR20/50/70 response: ≥20%, ≥50%, or ≥70% improvement, respectively, in swollen/tender joint count (66 joints assessed for swelling and 68 joints assessed for tenderness) and in at least 3 of 5 remaining ACR core measures: participant assessment of pain; participant global assessment of disease activity; physician global assessment of disease activity; self-assessed disability (disability index of the HAQ); and acute phase response: C-reactive protein (CRP) or ESR.
Weeks 0, 4, 8, 12, 16, 20, and 24
Percentage of Participants With European League Against Rheumatism (EULAR) Response Based on DAS28
Zeitfenster: Weeks 4, 8, 12, 16, 20, and 24
The DAS28-based EULAR response criteria were used to measure individual response as no effect, good effect, and moderate effect, depending on the extent of change from baseline and the level of disease activity reached. Good effect: change from baseline >1.2 with DAS28 score ≤3.2; moderate effect: change from baseline >1.2 with DAS28 score 3.2 to 5.1 or change from baseline >0.6 to <1.2 with DAS28 score <3.2; no effect: change from baseline ≤0.6 or change from baseline >0.6 and ≤1.2 with DAS28 score >5.1.
Weeks 4, 8, 12, 16, 20, and 24
C-Reactive Protein
Zeitfenster: Weeks 4, 8, 12, 16, 20, and 24
CRP (milligrams/Liter) is a mediator of inflammation, acute phase protein.
Weeks 4, 8, 12, 16, 20, and 24
Erythrocyte Sedimentation Rate
Zeitfenster: Weeks 4, 8, 12, 16, 20, and 24
ESR (mm/hr) is used to determine the acute phase response.
Weeks 4, 8, 12, 16, 20, and 24

Mitarbeiter und Ermittler

Hier finden Sie Personen und Organisationen, die an dieser Studie beteiligt sind.

Studienaufzeichnungsdaten

Diese Daten verfolgen den Fortschritt der Übermittlung von Studienaufzeichnungen und zusammenfassenden Ergebnissen an ClinicalTrials.gov. Studienaufzeichnungen und gemeldete Ergebnisse werden von der National Library of Medicine (NLM) überprüft, um sicherzustellen, dass sie bestimmten Qualitätskontrollstandards entsprechen, bevor sie auf der öffentlichen Website veröffentlicht werden.

Haupttermine studieren

Studienbeginn (Tatsächlich)

31. Oktober 2009

Primärer Abschluss (Tatsächlich)

14. Februar 2011

Studienabschluss (Tatsächlich)

14. Februar 2011

Studienanmeldedaten

Zuerst eingereicht

15. Oktober 2009

Zuerst eingereicht, das die QC-Kriterien erfüllt hat

15. Oktober 2009

Zuerst gepostet (Schätzen)

16. Oktober 2009

Studienaufzeichnungsaktualisierungen

Letztes Update gepostet (Tatsächlich)

29. März 2018

Letztes eingereichtes Update, das die QC-Kriterien erfüllt

28. Februar 2018

Zuletzt verifiziert

1. Februar 2018

Mehr Informationen

Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .

Abonnieren